Outdoor Exposure Patterns Associated With Less Myopic Shift in Children
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 14, 2024 -- Continuous outdoor exposure of at least 15 minutes accompanied with no less than 2,000 lux sunlight intensity is associated with less myopic shift among children, according to a study published online Aug. 13 in JAMA Network Open.
Jun Chen, Ph.D., from the Shanghai Eye Diseases Prevention and Treatment Center, and colleagues conducted a one-year prospective cohort study to examine the association of outdoor exposure patterns with myopic shift in children. Children without myopia who consistently wore a smartwatch for at least six hours daily, sustained for at least 90 days, were included in the study.
Data were included for 2,976 students (mean age, 7.2 years). The researchers found that the major outdoor exposure patterns of the 12 exposure patterns were those with time outdoors of at least 15 minutes, which accounted for 74.9 percent of minutes. Less myopic shift in refraction was seen for patterns with at least 15 minutes of outdoor exposure accompanied by a sunlight intensity of no less than 2,000 lux. Positive associations with less myopic shift were seen for isotemporal substitution of patterns with at least 15 minutes and 2,000 lux for other outdoor exposure patterns.
"These findings suggest that future outdoor intervention programs should focus not only on daily time outdoors but also the outdoor exposure patterns to prevent myopia," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-15 01:15
Read more
- USPSTF Recommends Screening for Domestic Violence in Pregnant, Postpartum Women
- PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission
- Onions in McDonalds' Quarter Pounders Linked to E. Coli Outbreak Have Been Recalled
- Current Tobacco Use Declining in U.S. Youth in 2024
- 2013 to 2021 Saw Decline in Benzodiazepine Initiation Post-AIS
- ASN: Hypertension Most Common Cardiovascular Comorbidity Seen With Dialysis
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions